Navigation Links
Breakthrough Testing for Patients on Aspirin Therapy for Preventing Heart Attacks

A new test has been developed to measure the effectiveness of Aspirin Therapy, based on research showing that up to 25% of patients are not experiencing the benefits of taking aspirin on a daily basis. The Aspirin Response Test gives the physician an opportunity to alter treatment methods for the patient, resulting in further prevention of heart attacks.

Los Angeles (PRWEB) October 21, 2008 -- Millions of Americans are taking aspirin to help prevent heart attacks and strokes. But what is not generally known is that up to 25% of patients on aspirin therapy receive little or no benefit from it. And because aspirin can cause stomach upset, ulcers, and even gastrointestinal bleeding, this question has become a significant medical concern. Now, breakthrough research may have an answer, according to Dr. Joseph Sciabbarrasi, an integrative medical doctor practicing in West Los Angeles. "We now have a simple urine test to determine if aspirin is actually helping prevent blood clots from forming."

The new Aspirin Response Test (ART) measures a substance, thromboxane B2 which is associated with the formation of blood clots. Aspirin is supposed to reduce the formation of this substance in the body. "We know that aspirin is working when thromboxane B2 levels are very low," says Dr. Sciabbarrasi. "If they are not, a physician can look for ways to reduce risk factors such as high cholesterol or blood sugar. It may be necessary to change the dose of aspirin or consider another medication as well."

The test performed by Spectracell Laboratories in Houston, was prompted by research which showed that people who do not respond to aspirin are three times more likely to have a fatal heart attack or stroke.

"It's a new, cutting edge clinical tool to help guide physicians and patients to what is working and what is not," Sciabbarrasi says. "It individualizes therapy and helps us better treat our patients who take aspirin."

"I had a heart attack last April," says Robert, a 52-year-old manager of a car dealership in Los Angeles and placed on aspirin therapy by his cardiologist. He had the ART done in July. Both he and his cardiologist were grateful.

"The aspirin was not protecting me from another clot," he explained. "My cardiologist was surprised and increased my dose. Thank goodness - the next test was in a good range."

For additional information on the Aspirin Response Test, contact Joy Ichikawa or visit

About Dr. Sciabbarrasi:
Dr. Sciabbarrasi offers cutting edge holistic and integrative medical care in a caring and supportive environment. His practice integrates conventional and complementary therapies including bioidentical hormone replacement therapy, cardiovascular health programs, immune system strengthening and intracellular nutrient and antioxidant analysis. His goal is to help individuals attain optimal health, often while undergoing conventional care. Dr. Sciabbarrasi's office is located at 2001 S. Barrington Ave, Suite 208, Los Angeles, CA 90025.

Joy Ichikawa, Patient Relations Director
Integrative Medicine, Joseph Sciabbarrasi, MD


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Breakthrough Baldness Genetic Test
2. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
3. Swiss Institute of Bioinformatics announces major breakthrough
4. A breakthrough in contrast-enhanced intraoperative ultrasonography
5. A new breakthrough in timing of urgent endoscopy for gastrointestinal bleeding patients
6. Dental Convention to Highlight Latest Breakthroughs in Dentistry
7. New discovery about growth factor can be breakthrough for cancer research
8. Sigma Breakthrough Technologies, Inc. (SBTI) Is Expanding Its Service Offering for Global Clients by Announcing the Public Listing of SBTI Europe GmbH
9. Presidential medal for technological breakthroughs earned by 2 chemical engineering professors
10. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
11. Wellcorps International Releases Breakthrough Multi-Benefit WellCapAM(TM) Activation Complex
Post Your Comments:
Related Image:
Breakthrough Testing for Patients on Aspirin Therapy for Preventing Heart Attacks 
(Date:11/30/2015)... ... December 01, 2015 , ... ... Colon as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... 2015 , ... Stress, anxiety, illness, infection or even a need for eyeglasses ... Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, ... tumors. , “Bad headaches that don’t go away, that don’t have any ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... ScanWise Implant, the industry,s first MRI guided user interface ... scanning of patients with MR Conditional implants, such as ... the 2015 Radiological Society of North America Annual ... exams and supports diagnostic confidence of this growing patient ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology: